Clementia Pharmaceuticals Inc (CMTA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Clementia Pharmaceuticals Inc (CMTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014309
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clementia Pharmaceuticals Inc (Clementia) is a biopharmaceutical company that develops and commercializes orphan drugs and therapies. The company’s palovarotene is used for treatment of muscle tissue disorders such as fibrodysplasia ossificans progressive and other diseases. Its palovarotene is an investigational retinoic acid receptor gamma agonist, and an oral therapy used to prevent the abnormal growth of bone in people with FOP. Clementia undertakes clinical trial for palovarotene in fibrodysplasia ossificans progressiva. The company operates through physician experts, researchers, and the rare disease community to study the treatment of FOP by tracking the natural course of the disease. It has presence in the US and Canada. Clementia is headquartered in Montreal, Quebec, Canada.

Clementia Pharmaceuticals Inc (CMTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Clementia Pharma Secures USD60 Million Venture Financing 11
Clementia Pharma Raises USD60 Million in Venture Financing 13
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 15
Clementia Pharma Raises US$20.8 Million In Series A Financing 16
Partnerships 17
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 17
Licensing Agreements 18
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 18
Clementia Pharma to Enter into License Agreement with Sanford Burnham Prebys Medical 19
Clementia Pharma Enters into Licensing Agreement with Yamaguchi University 20
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 21
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 22
Equity Offering 24
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc – Key Competitors 27
Clementia Pharmaceuticals Inc – Key Employees 28
Clementia Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 13, 2017: Clementia Reports Third Quarter 2017 Financial Results and Business Highlights 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Clementia Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Clementia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Clementia Pharma Secures USD60 Million Venture Financing 11
Clementia Pharma Raises USD60 Million in Venture Financing 13
Clementia Pharma Raises USD8.5 Million in Extended Series A Venture Financing 15
Clementia Pharma Raises US$20.8 Million In Series A Financing 16
Clementia Pharma Enters into Agreement with Instituto Ortopedico Rizzoli 17
Clementia Pharma Enters into Licensing Agreement with Galderma R&D 18
Clementia Pharma to Enter into License Agreement with Sanford Burnham Prebys Medical 19
Clementia Pharma Enters into Licensing Agreement with Yamaguchi University 20
Clementia Pharma Enters into Licensing Agreement with Thomas Jefferson University 21
Clementia Pharma Enters into Licensing Agreement with F. Hoffmann-La Roche 22
Clementia Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 24
Clementia Pharma Raises USD10 Million in Private Placement of Shares 26
Clementia Pharmaceuticals Inc, Key Competitors 27
Clementia Pharmaceuticals Inc, Key Employees 28
Clementia Pharmaceuticals Inc, Other Locations 29
Clementia Pharmaceuticals Inc, Subsidiaries 29

★海外企業調査レポート[Clementia Pharmaceuticals Inc (CMTA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compania Espanola de Petroleos SAU:石油・ガス:M&Aディール及び事業提携情報
    Summary Compania Espanola de Petroleos SAU (CEPSA) is an integrated energy company. It explores for, produces, refines, transports, and markets and sells crude oil, petroleum products, and natural gas. The company also generates and sells electricity and thermal power to industrial customers and con …
  • PowerStream Inc.-エネルギー分野:企業M&A・提携分析
    Summary PowerStream Inc. (PowerStream), a subsidiary of PowerStream Holdings, Inc., is a municipality-owned energy company that provides power and related services north of Toronto and in Central Ontario. The company is jointly owned by the municipality of Markham, municipality of Vaughan, and munic …
  • Nippon Soda Co., Ltd. (4041):企業の財務・戦略的SWOT分析
    Nippon Soda Co., Ltd. (4041) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • iMDsoft Inc:企業の戦略的SWOT分析
    iMDsoft Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • CytoDel Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CytoDel Inc (CytoDel) is a biopharmaceutical company that utilizes molecular biology tools to produce recombinant derivatives of botulinum neurotoxin (BoNT). The company provides product portfolio such as Ctyo-111, an antidote to botulism; and Cyto-012 a recombinant BoNT derivative, among ot …
  • Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is …
  • The Netherlands Cancer Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary The Netherlands Cancer Institute (NCI) is a research institute that offers cancer research and treatment services. The institute conducts research in the areas of cell biology, diagnostic oncology, medical oncology, molecular carcinogenesis, biochemistry, biological stress response, gene reg …
  • MediciNova Inc (MNOV):製薬・医療:M&Aディール及び事業提携情報
    Summary MediciNova Inc (MediciNova) focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and …
  • DCP Midstream LP (DCP):企業の財務・戦略的SWOT分析
    DCP Midstream LP (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Tenaga Nasional Berhad:戦略・SWOT・企業財務分析
    Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Tenaga Nasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Celsia SA ESP (CELSIA):企業の財務・戦略的SWOT分析
    Summary Celsia SA ESP (Celsia), formerly Compania Colombiana de Inversiones SA ESP, a subsidiary of Grupo Argos SA, is an energy company that generates, transmits, distributes, and sells electricity. The company’s product categories include home line, solar energy, backup energy, thermal network, ef …
  • Verizon Communications Inc (VZ):企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Genomic Health Inc (GHDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • 7-Eleven Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary 7-Eleven, Inc (7-Eleven) a subsidiary of Seven-Eleven Japan Co., Ltd., is a convenience store chain operator. The company operates through franchise and license models and offers a range of merchandises. It also operates as an independent gasoline retailer. The company’s store offers various …
  • Capricor Therapeutics Inc (CAPR):企業の財務・戦略的SWOT分析
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Baylor College of Medicine:企業のM&A・事業提携・投資動向
    Baylor College of Medicine - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Baylor College of Medicine Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • IOL Chemicals and Pharmaceuticals Ltd (IOLCP):企業の財務・戦略的SWOT分析
    IOL Chemicals and Pharmaceuticals Ltd (IOLCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • NeuroMetrix Inc (NURO):企業の財務・戦略的SWOT分析
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International), formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, …
  • Saudi Pharmaceutical Industries & Medical Appliances Corp (2070):製薬・医療:M&Aディール及び事業提携情報
    Summary Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO) develops, manufactures, and sells pharmaceutical products and medical appliances. The company offers its products in anti-infectives, cardio-vascular, diabetes, GIT, iron supplement, men health, musculoskeletal, pschychatric …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆